NTRK1 and angiosarcoma: In light of the paucity of genomic profiling or the application of targeted therapy in paediatric angiosarcoma, we present an unprecedented challenging case and demonstrate a durable clinical response to TRK inhibitor (larotrectinib) based upon a precision oncology approach using next-generation sequencing-based comprehensive genomic profiling.